https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Inpatient signs and symptoms and factors associated with death in children aged 5 years and younger admitted to two ebola management centres in Sierra Leone, 2014: a retrospective cohort study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27693 Wed 11 Apr 2018 10:30:05 AEST ]]> Cancer incidence and cancer death in relation to tobacco smoking in a population-based Australian cohort study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48997 35 cigarettes/day. Lung cancer risk was lower with quitting at any age but remained higher than never-smokers for quitters aged >25y. By age 80y, an estimated 48.3% of current-smokers (41.1% never-smokers) will develop cancer, and 14% will develop lung cancer, including 7.7% currently smoking 1-5 cigarettes/day and 26.4% for >35 cigarettes/day (1.0% never-smokers). Cancer risk for Australian smokers is significant, even for 'light' smokers. These contemporary estimates underpin the need for continued investment in strategies to prevent smoking uptake and facilitate cessation, which remain key to reducing cancer morbidity and mortality worldwide.]]> Wed 03 May 2023 12:03:16 AEST ]]> The feasibility and acceptability of implementing and evaluating a caregiver group intervention to address child mental health: A pilot study in Iraq https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50938 Mon 14 Aug 2023 12:58:09 AEST ]]> Socioeconomic variation in incidence of primary and secondary major cardiovascular disease events: an Australian population-based prospective cohort study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25323 64 years). Conclusions: Individual-level data are important for quantifying socioeconomic variation in CVD incidence, which is shown to be substantial among both those with and without prior CVD. Findings reinforce the opportunity for, and importance of, primary and secondary prevention and treatment in reducing socioeconomic variation in CVD and consequently the overall burden of CVD morbidity and mortality in Australia.]]> Fri 22 Apr 2022 10:26:20 AEST ]]>